TITLE

Moving from opacity to transparency in pharmaceutical policy

AUTHOR(S)
Dhalla, Irfan; Laupacis, Andreas
PUB. DATE
February 2008
SOURCE
CMAJ: Canadian Medical Association Journal;2/12/2008, Vol. 178 Issue 4, p428
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The authors reflect on the transparency of pharmaceutical policy in Canada. They argue that transparency in pharmaceutical policy-making may increase confidence in decision-making process and better decisions. They note that researchers, governments, quasi-governmental agencies, payers and medical journals should make more information available to the public. They predict that the country could be a world leader in this policy.
ACCESSION #
28802122

 

Related Articles

  • Waits for Access to New Biological and Pharmaceutical Medicines: Evidence of Government Failure. Skinner, Brett J.; Rovere, Mark // Fraser Forum;Jun2007, p7 

    The article presents the evidences of the delayed approval of drugs by the federal government in Canada. According to a study, provincial officials wait longer to make such drugs eligible despite being declared safe and effective by Health Canada due to differences involving the kind of drugs...

  • Transparency in drug regulation: Mirage or oasis? Lexchin, Joel; Mintzes, Barbara // CMAJ: Canadian Medical Association Journal;11/23/2004, Vol. 171 Issue 11, p1363 

    Comments on the legal protection of information used to approve new drugs in Canada. Reason behind the legal protection of drug regulation data; Disadvantages of non-disclosure to the Canadian Therapeutic Products Directorate; Comparison between U.S. and Canadian drug approval policies.

  • Editorial: Drug Regulation and Drug Information--Who Should Do What to Whom? Avorn, Jerry // American Journal of Public Health;Jan1995, Vol. 85 Issue 1, p18 

    The article comments on issues regarding drug regulation and drug information in the U.S. In the middle of the century, the U.S. tried to distinguish among ingested chemicals to reconcile the demands of public health as well as the needs of specific patients. On the issue of drug control, the...

  • Rx reimportation falls out of favor. Gonzalez, Gloria // Business Insurance;9/4/2006, Vol. 40 Issue 36, p1 

    The article relates the various reasons why the U.S. government does not consider the reimportation of prescription drugs from Canada a pressing issue anymore. The implementation of the Medicare Part D prescription drug benefit, along with several other factors, have lessened demand for...

  • Keeping a controlled drugs register. Dewbury, Christine // Pulse;9/27/2004, Vol. 64 Issue 38, p37 

    Discusses the requirements for a controlled drug register in Great Britain. Need for the register to be bounded and not loose leaf; Avoiding cancellation, obliteration and alteration of entries.

  • How the law keeps us ill. Hanlon, Michael // New Statesman;7/23/2001, Vol. 130 Issue 4547, p31 

    Focuses on the impact of the regulatory regimen for drug approvals that imposes high costs on the distribution of drugs. Financial burden on drug firms; Surveillance to detect complications; Issue on the fear of litigation.

  • Drug policy reform - the opportunity presented by 'legal highs'. Meacher, Molly C. // Psychiatrist;8/ 1/2013, Vol. 37 Issue 8, p249 

    Summary Current UK policy on drugs does little to reduce the potential harms to young people using drugs and in some ways can exacerbate them. The dramatic increase in the number of new psychoactive substances available in the UK carries the risk of increasing those harms and demands a new...

  • Using And Misusing Anecdote In Policy Making. McDonough, John E. // Health Affairs;Jan/Feb2001, Vol. 20 Issue 1, p207 

    Evaluates the use of anecdotes in making public health policies in the United States. Overlap of careful policy analysis by anecdotes; Details on anecdotes used for bolstering competing values; Identification of neglected policy problems.

  • NICE methodological guidelines and decision making in the National Health Service in England and Wales. Gafni, A.; Birch, S.; Gafni, Amiram; Birch, Stephen; NICE; National Health Service // PharmacoEconomics;2003, Vol. 21 Issue 3, p149 

    The National Institute for Clinical Excellence (NICE) responds to requests by the Department of Health for guidance on the use of selected new and established technologies in the National Health Service (NHS) in England and Wales. This paper asks whether the NICE methodological guidelines help...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics